Amedisys Inc (NASDAQ:AMED) – Analysts at SunTrust Banks lifted their Q3 2017 earnings per share (EPS) estimates for Amedisys in a note issued to investors on Thursday. SunTrust Banks analyst D. Macdonald now expects that the health services provider will earn $0.54 per share for the quarter, up from their prior forecast of $0.53. SunTrust Banks also issued estimates for Amedisys’ FY2017 earnings at $2.22 EPS, Q1 2018 earnings at $0.58 EPS, Q2 2018 earnings at $0.63 EPS, Q3 2018 earnings at $0.66 EPS, FY2018 earnings at $2.58 EPS and FY2019 earnings at $2.88 EPS.
AMED has been the topic of a number of other research reports. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Wednesday, July 26th. Stephens boosted their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 4th. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $56.50.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/08/19/q3-2017-earnings-forecast-for-amedisys-inc-nasdaqamed-issued-by-suntrust-banks-updated-updated.html.
Shares of Amedisys (AMED) opened at 47.36 on Monday. The company has a 50-day moving average price of $59.94 and a 200-day moving average price of $54.20. The company has a market capitalization of $1.60 billion, a P/E ratio of 40.48 and a beta of 0.94. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. Amedisys’s revenue was up 5.0% on a year-over-year basis. During the same period last year, the company earned $0.42 earnings per share.
Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Amedisys during the first quarter valued at approximately $123,000. State of Alaska Department of Revenue raised its position in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares during the period. CIBC Asset Management Inc acquired a new position in shares of Amedisys during the second quarter valued at approximately $230,000. Redmile Group LLC acquired a new position in shares of Amedisys during the first quarter valued at approximately $247,000. Finally, Suntrust Banks Inc. raised its position in shares of Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock valued at $279,000 after buying an additional 107 shares during the period. 97.81% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Lawrence R. Pernosky sold 11,500 shares of the company’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $58.97, for a total value of $678,155.00. Following the transaction, the insider now owns 30,093 shares of the company’s stock, valued at approximately $1,774,584.21. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Scott G. Ginn sold 23,828 shares of the company’s stock in a transaction on Monday, May 8th. The shares were sold at an average price of $58.62, for a total value of $1,396,797.36. Following the completion of the transaction, the insider now directly owns 13,018 shares in the company, valued at approximately $763,115.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,828 shares of company stock worth $3,350,922. Corporate insiders own 2.80% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
What are top analysts saying about Amedisys Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amedisys Inc and related companies.